Kornimate/medical-research-clean huggingface dataset:
effect of botulinum toxin to hallux valgus in addition to total contact insole

Conditions: Hallux Valgus

Summary: the investigators propose a new therapeutic approach by injecting botulinum toxin type a (bta) to the oblique and transverse heads of adductor muscle of the great toe. bta works by binding presynaptically to high-affinity recognition sites on the cholinergic nerve terminals and decrease the release of acetylcholine, causing a neuromuscular blocking effect. the investigators hypothesize that bta injection may help to decrease the hallux valgus angle by decrease adductor hallucis muscle activation. thereby enhance the therapeutic result of hallux valgus treated with total contact insole. the outcome measurement may shed light in treating patient with painful hallux valgus and document evidence for plantar pressure changes in acute, sub-acute and chronic stage.

this is a randomized, double-blind, placebo-controlled prospective study to assess the influence and efficacy of intramuscular (im) botulinum toxin type a (bta) injection in patients with painful hallux valgus with the use of total contact insole. fifty feet with painful hallux valgus will be collected. informed consent is obtained according to the hospital's medical ethics and the human clinical trial committee. the feet will be randomized into 2 groups: group a (n=25, treatment group) and group b (n=25, control group). clinical diagnosis of hallux valgus is made based on observation of great toe lateral deviation. inclusion criteria were hallux valgus with angle of at least 20°, single or bilateral hallux valgus. to obtain the hallux valgus angle, foot roentgenography in ap and sesamoid views under the weight bearing condition will be obtained. the angle formed by lines drawn to bisect the first metatarsal bone and the proximal phalanx of the great toe will be measured. the exclusion criteria include history of foot operations, rheumatoid and gouty arthritis, and any contraindication to bta administration. subjective data such as the foot function index will be collected.

Eligibility criteria:
inclusion criteria: * hallux valgus with angle of at least 20°, * single or bilateral hallux valgus. exclusion criteria: * history of foot operations, * rheumatoid arthritis and gouty arthritis. * any contraindication on bta administration

Keywords: botulinum toxin type a hallux valgus angle foot function index vas pain scale
the efficacy and safety of js002 pfs and ai in patients with primary hypercholesterolemia and mixed hyperlipidemia

Conditions: Hyperlipemia

Summary: js002 is a recombinant humanized anti-pcsk9 monoclonal antibody. this is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of js002 prefilled syringes and prefilled autosyringes in patients with primary hypercholesterolemia and mixed hyperlipidemia when combined with statin therapy. in this study, one dose group (150 mg) were set up in this study. 240 subjects are plan to be enrolled (the study drug will be assigned to a 2:1 :2:1ratio of js002 pfs / placebo or js002 ai / placebo ). each subject required a maximum of 6 weeks of screening, 12 weeks of treatment, and 8 weeks of follow-up.


Eligibility criteria:
inclusion criteria: 1. signed informed consent. 2. age 18\~80 years old; 3. stable optimized llt at least 4 weeks before randomization; 4. two times of fasting triglycerides ≤4.5 mmol/l(400mg/dl)at the time of screening; exclusion criteria: 1. history of nyha class iii-iv heart failure or ef\<30%; 2. history of uncontrolled arrhythmia within 90 days; 3. history of mi,ua, pci or cabg, stroke within 90 days; 4. known hemorrhagic stroke disease; 5. planned cardiac surgery or revascularization. 6. uncontrolled hypertension. 7. uncontrolled diabetes mellitius (hba1c\>8.0%）. 8. other conditions that the researchers considered inappropriate to participate in the study.
efficiency of patellar taping in treatment of patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: patellar subluxation is a common disorder that may cause patellofemoral pain syndrome. the efficiency of patellar taping in the treatment of patellofemoral pain syndrome has been reported good outcomes in most patients. however, some studies reported less effective in patients with higher body mass index, larger lateral patellofemoral angle, and smaller q angle. the investigators hypothesized that femoral internal rotation is a negative factor to the patellar taping. the investigators enroll consecutive 100 patients with anterior knee pain and radiographic evidence of patellar subluxation. the investigators determine femoral rotation via physical examination. the visual analogue scale was evaluate to compare the result between the those with and without femoral internal rotation.

consecutive 100 patients with anterior knee pain and compatible with inclusion criteria. before treatment, an independent physiotherapist evaluates whether femoral internal rotation or not via physical therapy, and another studying nurse records the visual analog scale and measures q angle. after evaluation, mcconnell taping is applied to these patients. two weeks later, outcomes are recorded including visual analog scale, satisfactory, and complication. the outcomes are compared between those with and without femoral internal rotation.

Eligibility criteria:
inclusion criteria: * anterior knee pain * radiographic evidence of patellar subluxation exclusion criteria: * history of patellar dislocation * osteoarthritis of ipsilateral knee * pregnancy * history of knee injury * bmi \> 35 * allergy to taping
efficacy and safety of memantine for parkinson's disease dementia (pdd) and dementia with lewy bodies (dlb)

Conditions: Dementia Associated With Parkinson's Disease; Dementia With Lewy Bodies

Summary: a 24-week placebo-controlled parallel group multicentre trial to study the safety and efficacy of memantine in patients with dementia associated with parkinson's disease and dementia with lewy bodies. it is hypothesized that memantine will be safe and well tolerated, and more effective than placebo.


Eligibility criteria:
inclusion criteria: * a diagnosis of parkinson's disease (larsen and dupont, 1994) and dementia (dsm iv(1987; 1994), or dementia with lewy bodies (mckeith et al. neurology 2005) * mild-to-moderate or moderate dementia (i.e. mmse 12-26, inclusive) * the subject has given a written informed consent * the subject is able and willing to comply with the study procedures and has a reliable caregiver (i.e. relative or nurse/nurse assistant who sees the patient at least weekly) exclusion criteria: * other brain disease of sufficient severity to cause dementia * mental retardation * terminal illness with life expectancy shorter than 6 months * recent major changes in health status * known epilepsy or previous convulsive seizure * major depression * severe dementia as defined by a mini-mental state examination score of 12 or lower * moderate to severe renal impairment (i.e. serum creatinine \> 1,5 upper limit normal (uln) or creatinin clearance \< 40ml/minute/1,73 m2 * moderate or severe heart disease (nyha iii-iv) * moderate or severe pulmonal disease * moderate to severe hepatic impairment (bilirubin or transaminases \> 2 times uln * women of childbearing potential (i.e. not post-menopausal and not taking contraceptive * the subjects is lactating * any laboratory value(s) exceeding the limits of normality if deemed to be clinically relevant by the study physician * known allergies to the investigational product

Keywords: dementia associated with parkinson's disease dementia with lewy bodies memantine placebo-controlled parallel group
effect of liraglutide for weight management in paediatric subjects with prader-willi syndrome

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted globally. the aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with prader-willi syndrome.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * confirmed diagnosis of pws (prader-willi syndrome) (by genetic testing) * male or female, age at the time of signing informed consent: - part a: above or equal to 12 years and less than 18 years * tanner stage 2-5 pubertal development for part a, and tanner stage 1 for part b * bmi (body mass index) corresponding to equal or above 30 kg/m\^2 for adults by international cut-off points1 and equal or above the 95th percentile for age and sex (for diagnosis of obesity) * stable body weight during the previous 90 days before screening ( below 10 kg self-reported weight change) * testing has been performed to evaluate for adrenal insufficiency and documented in medical record exclusion criteria: * type 1 diabetes mellitus (t1dm) * type 2 diabetes mellitus (t2dm) * calcitonin equal or above 50 ng/l * no change in treatment plan with growth hormone (gh) from randomisation to the end of the open-label period patients on growth hormone to stay on, patients off gh to stay off during this period. adjustments in doses of growth hormone will be permitted) * family or personal history of multiple endocrine neoplasia type 2 (men2) or medullary thyroids carcinoma (mtc) * history of pancreatitis (acute or chronic) * treatment with any medication prescribed for weight loss within 90 days before screening (e.g. orlistat, zonisamide, topiramate/phentermine, lorcaserin, phentermine, bupropion/naltrexone,liraglutide, metformin) * untreated adrenal insufficiency * suggestive history of, or significant risk of gastroparesis (e.g. marked abdominal bloating post meal, history of vomiting, severe constipation), as judged by the investigator
intestinal microbiota and treatment of gd

Conditions: Microbiota

Summary: graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. investigators systematically performed a comparative analysis of the gut microbiota in gd patients and healthy controls and analyse the relationship between intestinal microbiota and gd drug therapy.

graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. investigators systematically performed a comparative analysis of the gut microbiota in gd patients and healthy controls before and found that gut microbiota changed between gd patients and healthy controls.but there are few articles on the relationship between intestinal microbiota and drug treatment of gd, so investigators explored the relationship between intestinal microflora and methimazole treatment for gd.

Eligibility criteria:
inclusion criteria: * aged 18 to 65 years * gd was clinical diagnosed and accept the standard treatment of methimazole or propylthiouracil and thyroid function returned to normal exclusion criteria: * pregnancy * lactation * cigarette smoking * alcohol addiction * hypertension * diabetes mellitus * lipid dysregulation * bmi \> 27 * recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or chinese herbal medicine * history of disease with an autoimmune component, such as ms, rheumatoid arthritis, ibs, or ibd * history of malignancy or any gastrointestinal tract surgery

Keywords: gut microbiota 16s rrna gene graves' disease methimazole propylthiouracil
investigating the impact of ex vivo ozone injection on synovial fluids in patients diagnosed with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the objective of this study is to examine the effect of varying ozone doses on the levels of pro-inflammatory cytokines in synovial fluid collected from individuals with knee osteoarthritis.

in this study, synovial fluid samples will be collected from patients diagnosed with knee osteoarthritis for in vitro studies. the synovial fluid will be collected under sterile conditions by a joint puncture, and ultrasonography will be performed before sample collection. the synovial fluid samples will then be transferred to sterile urine culture tubes, with one containing only synovial fluid and the others containing synovial fluid and ozone gas. afterward, the synovial fluid samples will be centrifuged, and the upper portion will be stored at -80°c for biochemical analyses. the total protein content will be measured using a commercial kit based on the bradford method, and the total antioxidant level and total oxidant levels will be measured using commercially purchased kits according to the manufacturer's instructions. the oxidative stress index will be calculated using the formula (tos/tas) and will be normalized to the total protein content measured in the synovial fluid.

Eligibility criteria:
inclusion criteria: * being diagnosed with knee osteoarthritis. * giving consent to participate in the study. exclusion criteria: - not giving consent.

Keywords: dose-dependent effect knee osteoarthritis ozone therapy pro-inflammatory cytokines synovial fluid
overweight adults--ethnic, ses and behavioral influences

Conditions: Cardiovascular Diseases; Heart Diseases; Obesity

Summary: to examine the effects of ethnicity, socioeconomic status (ses) and behavior in overweight adults.

background: in 1999, more than 55 percent of united states adults were overweight, an increase of 8 percent in fifteen years. because overweight is associated with cardiovascular disease (cvd) morbidity and mortality, the alarming increase in overweight underscored the need for innovative and effective weight-loss interventions. tailored interventions specifically designed for high-risk subgroups can compliment existing population-based approaches. however, before designing such interventions, sociodemographic characteristics of those at high risk must be identified.. although past studies have shown that ethnicity is associated with overweight, these studies suffered from potential confounding from ses because ethnic minority groups are disproportionately poor. past studies have been compromised by limited sample size at the extremes of ses such as higher ses mexican-americans or blacks, and/or lower ses whites. weight loss is affected by multiple perceptions and behaviors, such as perceptions of overweight, physical activity, dietary habits, smoking, and alcohol use. although past epidemiological research has investigated the independent effects of such influences on weight, research to date has not identified whether distinct clusters of weight perceptions and behaviors exist among overweight adults. given that such clusters may differ by sociodemographic characteristics, identifying clusters may contribute to the design of innovative and tailored weight-loss interventions that address the presence of multiple influences on weight loss and increase the likelihood of successful interventions. design narrative: the study had four specific aims: (1) to identify subgroups at high risk of overweight based on sociodemographic characteristics (e.g., ethnicity and ses): (2a) to determine whether distinct clusters of weight perceptions and behaviors exist among overweight adults and (2b) to determine whether the clusters differ by sociodemographic characteristics; (3) to determine whether clusters in the overweight sample exist among normal-weight adults, and (4) to propose tailored weight-loss interventions to be tested empirically in the future. data were analyzed, by gender, for 3203 black, 2989 mexican-american, and 3761 white men and women, ages 25-64, who participated in the third national health and nutrition examination survey (nhanes iii), 1988-1994). this national survey of the united states population over-sampled by the two largest ethnic minorities, blacks and mexican-americans, and provided sufficient sample sizes at the extremes of ses.

Eligibility criteria:
no eligibility criteria
cardiovascular outcomes in bariatric surgery patients with type 2 diabetes

Conditions: Obesity; Type2 Diabetes; Bariatric Surgery Candidate

Summary: the objective of the analysis was to evaluate the relationship between bariatric surgery and cardiovascular outcomes in obese patients with type 2 diabetes. this is a retrospective matched cohort study of patients with diabetes that underwent bariatric surgery at the cleveland clinic between 2004-2017. each bariatric patient was matched to a non-surgical control with obesity and type 2 diabetes in a 1:5 ratio using data from the electronic medical record (emr). the maximum observation time was 10 years. cumulative incidence rates for all-cause mortality and cardiovascular events were calculated at years 1, 3, 5, 7 and 10. kaplan-meier curves were created for all the outcomes with all-cause mortality considered as a completing risk.


Eligibility criteria:
inclusion criteria: * type ii diabetes * 18-80 years old * bmi\>=30 * hba1c \>6.4 or taking at lease one (1) diabetes medication (insulin or non-insulin) exclusion criteria: * history of liver, heart, or lung transplant * emergency department admission within 5 days prior * cancer diagnosis within 1 year prior * any prior ejection fraction \<20% * non-surgical controls were excluded if they died within 30 days after the index date (date of surgery for the bariatric patients) * last follow-up date on or before the index date
epidemiology of high-risk hpv infection in women participating in a pilot screening program for cervical cancer

Conditions: HPV Infection

Summary: cervical cancer is due to a persistent infection with a group of viruses known as high-risk human papillomaviruses (hrhpv). viral dna can be easily detected in a cervical sample by a procedure called 'hpv testing', which can be used as a relevant screening test. a pilot screening program called start-hpv has been set up in the ardennes, a french administrative area localized in the north of france, with hpv testing as a primary screening test.this observational study aimed to evaluate hrhpv genotypes repartition in the population who participate in the start-hpv screening program. this study will allow a better knowledge of hrhpv infection epidemiology in a screened population.


Eligibility criteria:
inclusion criteria: * to live in the ardennes department (france) * affiliation to a health insurance organism * 31 to 65 years old exclusion criteria: * current follow-up for cervical cytological abnormalities * history of hysterectomy * reimbursement for a pap smear in the last 3 years
the impact of the "stone md" mobile app on the prevention of forgotten ureteral stents

Conditions: Urolithiasis

Summary: the impact of the "stone md" mobile app on the prevention of forgotten ureteral stents

inclusion criteria: 1. male and female patients aged 18 to 80 years who have a ch 4.7-6.0 polyurethane ureteral stent exclusion criteria: 1. active phase of urinary tract infection 2. insufficient level of social adaptation 3. the patient does not have a smartphone with internet access all patients will be randomized into 2 groups: * group a - patients who used the stone md mobile application * group b - patients who did not use the mobile application patients are to be assigned a randomization number that will match their treatment. block randomization using 10 blocks is to be performed by a central randomization organization (www.randomize.net) using a computerized algorithm. "stent radar" - part of the "stone md" mobile application. this tool is designed for the patient to remove the ureteral stent using a mobile application within the time period prescribed by the doctor. after the operation, the patient independently enters the data related to the installation of the stent in the stent radar section of the stone md mobile application. this data includes: the name of the stent, the side of insertion, and the estimated date of removal. in a few days, a push notification appears in the application stating that it is necessary to consult a doctor for the timely removal of the stent. thus, it is almost impossible to forget to remove the stent. at discharge, we strongly recommend that all patients install the stone md mobile app on their smartphone. in the postoperative period, all patients will be monitored. in the event that 2 weeks after the expected date of removal, the patient does not get in touch, he will receive a call from the clinic, reminding him of the necessary visit (to remove the stent). primary assessed outcomes: 1. number of patients who removed the stent on time in both groups 2. number of patients who delayed stent removal in both groups (less than 14 days) 3. number of patients who forgot to remove the stent in both groups (removed the stent more than 14 days from the expected date of removal) secondary assessed outcomes: 1. assessment of stone-free status after surgery by performing computed tomography of kidneys and urinary tract without intravenous contrasting 1 month after surgery

Eligibility criteria:
inclusion criteria: 1. male and female patients aged 18 to 80 years who have a ch 4.7-6.0 polyurethane ureteral stent exclusion criteria: 1. active phase of urinary tract infection 2. insufficient level of social adaptation 3. the patient does not have a smartphone with internet access